ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Oxygenta Pharmaceutical Limited conducted its 33rd Annual General Meeting on August 21, 2026, via video conferencing to discuss and adopt various corporate business resolutions.
Oxygenta Pharmaceutical has submitted its 33rd Annual Report for FY 2025-26, including the notice for the upcoming Annual General Meeting scheduled for August 21, 2026.
Oxygenta Pharmaceutical Limited announced its 33rd Annual General Meeting scheduled for August 21, 2026. The notice includes director appointments and adoption of the company's financial statements.
Oxygenta Pharmaceutical Limited has appointed M/s. PCR & Associates as its Cost Auditor for a 12-month term. This appointment follows the company's recent board meeting.
Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹37 Cr (+145.0% YoY) and a net loss of ₹2.1 Cr for Q1 FY27.
Oxygenta Pharmaceutical Ltd has scheduled a board meeting on July 25, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Oxygenta Pharmaceutical Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with SEBI regulatory requirements.
Oxygenta Pharmaceutical Ltd reported revenue from operations of ₹49.6 Cr (+0.2% YoY) and a net loss of ₹1.7 Cr for Q4 FY26.
Oxygenta Pharmaceutical Limited reported its audited financial results for the year ended March 31, 2026. The company also announced key board appointments and auditor changes.
Oxygenta Pharmaceutical scheduled a board meeting for May 23, 2026. Directors will consider audited financial results for the quarter and year ended March 2026.